Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Patent
1994-02-18
1995-02-14
Hook, Gregory
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
514162, 514629, 514630, A61K 3160, A61K 31615, A61K 3116
Patent
active
053896211
ABSTRACT:
A method of enhancing the anticoagulant effect of aspirin is disclosed, wherein salicylamide is coadministered. Salicylamide is essentially without anticoagulant effects of its own. A normal dose of salicylamide, approximately 30 mg to about 3.0 grams administered daily, or about 3 to 9 mg/kg body weight, can increase the anticoagulant effect of aspirin. This is particularly desirable in patients who are undergoing long-term anticoagulant therapy, e.g., cardiac patients.
REFERENCES:
patent: 4329986 (1982-05-01), Babb
patent: 4528178 (1985-07-01), Babb
patent: 4885287 (1989-12-01), Hussain et al.
patent: 4943565 (1990-07-01), Tencza et al.
Abdel-Rahman, M. et al., Can. J. Physiol. Pharmacol. 69, pp. 1436-1442, 1992.
Ali, M. et al., Prostaglandin Med. 3, pp. 327-332, 1979.
Al-Nibdgurtm G., et al., Proc. Soc. Exp. Biol. Med., 1B3, pp. 632-636, 1970.
Austen, K., Drugs 33 (supp.) pp. 10-17, 1987.
Bakar, S. K., et al., J. Pharm. Sci., 72, pp. 1020-1023, 1983.
Barr, W. et al., Pharmacokinetics, A Modern View, pp. 426-429, Plenum press, New York, 1969.
Barr, W., Drug Inf. Bull. pp. 27-45 (Jan./Jun. 1969).
Barr, W. et al., Rev. Can. Biol., 32, (suppl.) pp. 31-42 1973.
Batterman, R. et al., J. Am. Med. Assoc., 159, pp. 1619-1622, 1955.
Baven, E. et al., J. Pharm. Pharmacol., 6 pp. 872-878, 1952.
Berger, F., Proc. Soc. Exp. Biol. Med., 87, pp. 449-451, 1954.
Borovsky, M., Am. J. Dis. Child., 100, pp. 23-30 1960.
Bradon, R. et al., Ther; Drug Monit., 7, pp. 216-221, 1985.
Braden, G., et al., Circulation, 84, pp. 679-685 (supp.) 1991.
Brandon, R., et al., Ther. Drug Monit. 7, pp. 216-221 (1985).
Brecher G. et al., Am. U. Clin Path. 23, pp. 15-26 (1953).
Brodie, D. et al., J. Am. Pharm. Assoc., 40, pp. 414-416 (1951).
Brune, K. et al., Gen. Pharmacol. 7, pp. 27-33 (1976).
Brune, K. et al., Br. J. Clin. Pharm., 10, pp. 279S-284S (1980).
Casadebaig, F. et al., Thromb. Res. 64, pp. 631-636 (1991).
Cerletti, C. et al., Biochem. Biophys, Acta., 714, pp. 122-128 (1982).
Cerletti, C., et al., Biochem. Biophys. Acta. 759, pp. 125 (1983).
Abattoni G., et al., Advances in Prostaglanin, Thromboxane and Leukotriene Research, 17, pp. 598-614 Raven Press, N.Y. (1988).
Clissold, S., Drugs, 32 (supp. 4) pp. 8-26 (1986).
Davison, C., Salicylates: An International Symposium, 81, J. & A. Churchill Ltd. London (1963).
Dejana, E. et al., J. Clin. Invest., 68, pp. 1108-1112 (1981).
Ellenhorn, M. J., et al., J. Am. Pharm. Assoc., NS6, pp. 62-65 (1966).
Fitzgerald, G., et al., J. Clin. Invest. 71, pp. 676-688 (1983).
Fitzgerald, G., et al., J. Pharmacol. Exp. Ther., 259, pp. 1043-1049 (1991).
Flower, R. et al., The Pharmacological Basis Of Therapeutics, 6, pp. 682-728 Macmillan Publishing Company, New York (1980).
Frolich, J., et al., Advances In Prostaglandin, Thromboxan, And Leukotriene Research, 19, pp. 211-215. Raven Press Ltd., N.Y. (1989).
Fuster, V., et al., N. Engl. J. Med. 321, pp. 183-185 (1989).
Gabrielsson, J., et al., Life Sci., 37, pp. 2275-2282 (1985).
Gaetano, G., et al., Circulation, 72, pp. 1185-1193 (1985).
Gatti, G., et al., Int. J. Clin. Pharmacol. Res. IX(6), pp. 385-389 (1989).
Gilman, A. G. ed., et al., Goodman And Gilman's The Pharmacological Basis Of Therapeutics 6th ed. Macmillan Pub., Co., N.Y. pp. 682-728 (1980).
Goldblatt, M., J. Soc. Chem. Ind. Lond., 52, pp. 1056-1057 (1935).
Graf, P. et al., Experientia, 31, pp. 951-953 (1975).
Graham, B., et al., Clin. Pharm. Ther., 22, pp. 410-420 (1977).
Hamberg, M., et al., Proc. Natl. Acad. Sci USA., 72, pp. 2994-2998 (1975).
Harrison, L., et al., J. Pharm. Sci., 69, pp. 1268 (1980).
Hart, E. R. J. Pharmacol. Exp. Ther., 89, pp. 205-209 (1947).
Hatori, A., et al., Eur. J. Drug Metab. Pharmacokinet, 9, pp. 205-214 (1984).
Hawkins, D., et al., Science, 160, pp. 780-781 (1968).
Hennekens, C., et al., Circulation, 80, pp. 749-756 (1989).
Hogden, C., et al., J. Pharmacol. Exp. Ther., 125, pp. 275-281 (1959).
Houston, J. B., et al., J. Pharmacol. Exp. Ther., 198, pp. 284-294 (1976).
Humes J., et al., Proc. Natl. Acad. Sci. USA. 78, pp. 2053-2061 (1981).
Iwamoto, K., et al., Biochem. Pharmacol., 35, pp. 687-689 (1983).
Iwamoto, K., et al., Biochem. Pharmacol., 33, pp. 3089-3095 (1984).
Koike, M., et al., J. Pharm. Sci., 70, pp. 308-311 (1981).
Kulmacz, R., et al., Mol. Pharmacol., 40, pp. 833-837 (1991).
Lasagna, L., Am. J. Med. Sci. 242, pp. 620-627 (1961).
Lefort, J., et al., Br. J. Pharmacol., 63, pp. 35-42 (1978).
Leonards, J. Proc Exp Biol. Med., 110, pp. 304-307 (1962).
Leonards, J. Clin. Pharmacol. Ther., 4, pp. 476-479 (1963).
Levy, G., Pediatrics, 62, pp. 867-872 (1978).
Levy, G., Br. J. Clin. Pharmacol., 10, pp. 285S-290S (1980).
Levy, G., J. Pharmacol. Exp. Ther., 54, pp. 1121-1125 (1965).
Levy, G. J. Pharmacol. Exp. Ther., 156, pp. 285-293 (1967).
Levy, G., J. Pharm. Sci., 57, pp. 1330-1335 (1968).
Levy, G., et al., J. Pharm. Sci., 60, pp. 608-611 (1971).
Lim, R. K., J. Pharmacol., 101, pp. 119-124 (1951).
Mahoney, C., Am. J. Cardiol, 64, pp. 387-389 (1989).
Marcus, A., N. Engl. J. Med., 297, p. 1284 (1977).
Martin, B. Advances in Pharmaceutical Sciences, 3, pp. 107-171, Academic Press, London (1971).
Mays, D., et al., J. Chromatogr. 311, pp. 310-309 (1984).
Merino, J., et al., Biochem. Pharmacol., 29, pp. 1093-1096 (1980).
Mikhailidis, D., et al., Pharmacotherapeutica, 4, pp. 255-1258 (1985).
Milne, M., Salicylates, An International Symposium 6-27 J. & A., Churchill Ltd., London (1963).
Moncada, S., et al., Nature, 263, pp. 663-665 (1976).
Morgan, A., et al., J. Pharm. Sci., 54, pp. 1640-1646 (1965).
Morris, M., et al., J. Pharm. Sci., 72, pp. 612-617 (1983).
Nelson, J., et al., J. Pharmacol. Exp. Ther., 153, pp. 159-166 (1966).
Pang, S., et al., J. Chromatogr., 420, pp. 313-327 (1987).
Patel., D., et al., Xenobiotica, 20, pp. 847-854 (1990).
Pederson, A., et al., N. Engl. J. Med., 331, pp. 1206-1211 (1984).
Peng, G., et al., J. Parm Sci., 67, pp. 710-712 (1978).
Pickard, R., et al., Nature, 219, pp. 68-69 (1968).
Quick, A. J., et al., J. Parmacol. Exp. Ther., 128, pp. 95-98 (1960).
Rainsford, K., et al., Biochem. Pharmacol., 32, pp. 1301-1308 (1983).
Rao, G., Prostaglandins Leukotriene Med., 30, pp. 133-145 (1987).
Riegelman, S., et al., J. Pharmacokinet. Biopharm., 1, pp. 419-434 (1973).
Roth, G., et al., J. Biol. Chem., 253, pp. 3782-3784 (1978).
Roth, G., et al., J. Clin. Invest., 56, pp. 624-632 (10975).
Rotilio, D., et al., Eur. J. Pharmacol., 97, pp. 197-208 (1984).
Rowland, M., et al., J. Pharm. Sci., 56, pp. 717-720 (1967).
Rowland, M. et al., J. Pharm. Sci., 61, pp. 379-385 (1972).
Rubin, G., et al., J. Pharm. Pharmacol., 35, pp. 115-117 (1983).
Rumble. R. H., et al., J. Chromatogr., 225, pp. 252-260 (1981).
Sagone, A., Jr., et al., J. Immunol., 138, pp. 2177-2183 (1987).
Schanker, L., et al., J. Pharmacol., Exp. Ther., 123, pp. 81-88 (1958).
Schreiber, T., Drugs, 38, pp. 180-184 (1989).
Seeberg, V., et al., J. Pharmacol. Exp. Ther., 101, pp. 275-282 (1951).
Seymour, R. A., Br. J. Clin. Pharmacol., 17, pp. 161-163 (1984).
Shibasaki, J., et al., J. Pharmacobiodyn., 4, pp. 91-100 (1981).
Shibasaki, J., et al., J. Pharmacobiodyn., 7, pp. 804-810 (1984).
Siegel, M., et al., Proc. Nat. Acad. Sci. USA., 76, pp. 3774-3779 (1979).
Smith B., et al., Chem. Biol. Interactions, 79, pp. 245-264 (1991).
Smith J., et al., Nature, 231, pp. 235-237 (1971).
Soldatos, C., et al., Pharmacol. 16, pp. 193-198 (1978).
Steering Committee of the "U.S. Physicians' Health Study" Research Group Final report on the aspirin component of the ongoing physicians health study, N. Engl. J. Med., 321, pp. 129-135 (1989).
Tayor, F., FDA Consumer, 14, pp. 13-16 (1980-1981).
Theroux, M., et al., N. Engl. J. Med., 319, pp. 1105-1111, (1988).
Vane, J., Nature, 231, pp. 232-235 (1971).
Vargaftig, B., J. Pharm. Pharmacol., 30, pp. 101-104 (1978a).
Vargaftig, B., Eur. J. Pharmacol., 50, pp. 321-241 (1978b).
Von Euler, U., Nauny Schmiedebergs Archiv fur Experimentelle Pathologie und Pharmakologie, 175, p. 78-84 (1934).
Wallenstein, S., et al., Federation Proc., 13, pp. 414 (1954).
Wan S., et al., J. Pharm. Sci., 61, pp. 1284-1287 (1972).
Waschek, J., et al., J. Pharmacok
Abdel-Rahman Mohamed S.
Rizk Maged M.
Hook Gregory
University of Medicine and Dentistry of New Jersey
LandOfFree
Method of enhancing the anticoagulant effects of aspirin using s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enhancing the anticoagulant effects of aspirin using s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing the anticoagulant effects of aspirin using s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-288100